Drugs / IODINE I 124 GIRENTUXIMAB
IODINE I 124 GIRENTUXIMAB
also known as
124I-cG250 · cG250 (124I) · Girentuximab i-124 · Girentuximab iodine-124 · Iodine (124i) girentuximab · Redectane
Monoclonal antibody targets CA9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01582204 | Apr 2012 → Apr 2027 expected | kidney cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IODINE I 124 GIRENTUXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108713 ↗ |
| Known as | 124I-cG250 | “following the lst inj of 124I-cG250” NCT01582204 ↗ |
| Known as | cG250 (124I) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108713 ↗ |
| Known as | Girentuximab i-124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108713 ↗ |
| Known as | Girentuximab iodine-124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108713 ↗ |
| Known as | Iodine (124i) girentuximab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108713 ↗ |
| Known as | Redectane | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108713 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108713 ↗ |
| Target | CA9 | “Carbonic anhydrase IX binding agent” CHEMBL2108713 ↗ |